Search Results

CSL Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.com/expertise/influenza/pandemic-response-solutions

Seqirus – a global leader in influenza prevention and a business of CSL Limited - has entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute.

https://www.seqirus.com/news/csls-seqirus-and-the-university-of-liverpool-pandemic-institute-launch-collaboration

CSL Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.

https://www.seqirus.com/manufacturing/global-manufacturing-network

CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.com/expertise

Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)

https://www.seqirus.com/news/seqirus-and-us-gov-renew-multi-year-agreement-for-influenza-pandemic-preparedness-and-response

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

https://www.seqirus.com/news/csl-enters-licensing-agreement-arcturus-therapeutics-next-gen-mrna-vaccine-technology

New data will be presented at the Options for the Control of Influenza (OPTIONS XI) conference taking place September 26-29, 2022 in Belfast, United Kingdom.

https://www.seqirus.com/news/csl-seqirus-to-highlight-commitment-to-influenza-protection-with-data-presentations-at-options-xi

Read the latest news from CSL Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news

Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives

https://www.seqirus.com/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines

Data published in Molecular Therapy – Methods and Clinical Development confirm the potential preclinical benefit of the sa-mRNA technology platform, the next generation of mRNA vaccine technology

https://www.seqirus.com/news/csl-announces-positive-preclinical-data-for-self-amplifying-messenger-rna-flu-vaccine-candidates